Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.990
-0.140 (-4.47%)
At close: Mar 24, 2026, 4:00 PM EDT
3.120
+0.130 (4.35%)
After-hours: Mar 24, 2026, 5:44 PM EDT
Xenetic Biosciences Revenue
In the year 2025, Xenetic Biosciences had annual revenue of $2.98M with 19.04% growth. Xenetic Biosciences had revenue of $766.30K in the quarter ending December 31, 2025, with 18.11% growth.
Revenue (ttm)
$2.98M
Revenue Growth
+19.04%
P/S Ratio
2.41
Revenue / Employee
$1,488,206
Employees
2
Market Cap
6.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.98M | 476.13K | 19.04% |
| Dec 31, 2024 | 2.50M | -39.70K | -1.56% |
| Dec 31, 2023 | 2.54M | 833.06K | 48.80% |
| Dec 31, 2022 | 1.71M | 546.23K | 47.06% |
| Dec 31, 2021 | 1.16M | 723.75K | 165.64% |
| Dec 31, 2020 | 436.94K | 419.88K | 2,460.31% |
| Dec 31, 2019 | 17.07K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 7.59M | 4.59M | 152.83% |
| Dec 31, 2016 | 3.00M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 1.00M | - | - |
| Sep 30, 2013 | - | - | - |
| Dec 31, 2012 | 293.60K | - | - |
| Aug 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 3.85M |
| CollPlant Biotechnologies | 2.48M |
| SciSparc | 1.31M |
| SeaStar Medical Holding | 881.00K |
| Addex Therapeutics | 198.82K |
| Kiora Pharmaceuticals | 20.00K |
| Alaunos Therapeutics | 6.00K |
| Ernexa Therapeutics | 1,000.00 |
XBIO News
- 11 days ago - Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results - Accesswire
- 3 months ago - Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Accesswire
- 4 months ago - Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform - Accesswire
- 4 months ago - Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results - Accesswire
- 5 months ago - Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - Accesswire
- 7 months ago - Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results - Accesswire
- 8 months ago - Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma - Accesswire
- 8 months ago - Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Accesswire